We have identified a fixed nonsynonymous sequence difference between humans (Val381; derived variant) and Neandertals (Ala381; ancestral variant) Cyp1b1 expression by PAHs (e.g. benzo(a)pyrene). The resulting CYP1A1/CYP1B1 enzymes are responsible for PAH first pass metabolism, which can result in the generation of toxic intermediates and perhaps AHR-associated toxicities. In contrast, the human AHR retains the ancestral sensitivity observed in primates to non-toxic endogenous AHR ligands (e.g. indole, indoxyl sulfate). Our findings reveal that a functionally significant change in the AHR occurred uniquely in humans, relative to other primates, that would attenuate the response to many environmental pollutants, including chemicals present in smoke from fire use during cooking.
Introduction
The Aryl hydrocarbon receptor (AHR) was initially identified as the receptor that bound with high affinity 2, 3, 7, . The AHR is the only member of the bHLH-PAS transcription factor family that is activated through binding ligands (Beischlag, et al. 2008) . The unliganded AHR resides in the cytoplasm bound to heat shock protein 90, X-associated protein 2 and p23. Upon ligand activation, the AHR complex translocates into the nucleus where a fraction of the receptor pool heterodimerizes with the Ah receptor nuclear translocator (ARNT). The AHR/ARNT heterodimer binds to dioxin responsive elements and induces the expression of genes involved in xenobiotic metabolism. The AHR is the predominant regulator, in conjunction with its dimerization partner ARNT, of 4 surveillance in epithelial barrier tissues in skin and the gastrointestinal tract. The ability of commensal yeast and bacteria to produce AHR ligands suggests that the host AHR has evolved to respond to the presence of the microbiota resulting in modulation of immune function (Gaitanis, et al. 2008; Zelante, et al. 2013 ). In the gastrointestinal tract activation of the AHR by dietary ligands during organogenesis enhances intestinal lymphoid follicle development (Kiss, et al. 2011) . Studies in Ahr -/-mice point to a role for the AHR in the maintenance of normal homeostasis in a variety of physiological pathways (Gonzalez and Fernandez-Salguero 1998) .
These observations would suggest that activation of AHR by endogenous and dietary ligands would be beneficial and likely conserved through evolution.
The rodent AHR homolog (e.g. AHR b in mice) is known to bind exogenous ligands such as TCDD and PAHs with ~10-fold higher affinity than the human AHR (Harper, et al. 1988; Ramadoss and Perdew 2004) . This difference has been attributed to an amino acid difference in the ligand-binding pocket, which is a valine at position 381 in human AHR instead of an alanine residue as observed in rodents at this position (Ramadoss and Perdew 2004) . These studies led to the concept that the human AHR possesses a global loss of ligand affinity relative to the rodent homolog. However, more recent reports have discovered that the human AHR has relatively higher affinity for a number of tryptophan-derived ligands, such as indirubin, indoxyl sufate, indole and kynurenic acid (Flaveny, et al. 2009; Hubbard, et al. 2015) . These latter studies would suggest that the ligand-binding pocket between rodents and humans exhibit differential ligand selectivity. The cause of differential AHR ligand selectivity between these species and the possible selective pressures that have lead to these differences is not known.
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Interestingly, studies examining fish populations within highly polluted habitats provide strong evidence for the notion that vertebrates can adapt to evolutionary pressure by persistent exposure to toxic environmental AHR ligands. The industrial release of highly concentrated planar polychlorinated biphenyls (PCBs), known to be potent AHR ligands, into the Hudson River has resulted in populations of Atlantic Tomcod that exhibit dramatically reduced ligandmediated AHR transcriptional activity (Yuan, et al. 2006) . Mechanistic studies revealed that 99% of the Hudson River Tomcod have an AHR-2 gene containing a 6 base pair deletion within the ligand-binding domain, that appears to explain the reduction in AHR activation (Wirgin, et al. 2011) . Similarly, Atlantic killifish populations from PCB contaminated habitats also show significantly attenuated AHR mediated transcriptional activity (Bello, et al. 2001) . These studies illustrate that toxic AHR ligands can mediate rapid change within a relatively small number of generations. In the fish examples discussed above, the evolutionary processes were likely driven by acute embryo mortality under conditions of AHR ligand overexposure.
Here we examine the molecular evolution of the AHR in primates and, more specifically, compare the transcriptional activity of Neandertal and human AHR. Analyses of AHR nucleotide sequences in various primate species revealed that the encoded valine at residue 381 that mediates low affinity for PAHs is present only in modern humans. Yet, our functional experiments demonstrate that the human AHR retains the sensitivity to endogenous ligand(s) observed in other primate AHR. These observations indicate that the human AHR have a reduced affinity for exogenous AHR ligands, perhaps conferring tolerance to environmental AHR ligand exposures.
Results

The human AHR contains a V381 residue that is unique among primates examined
Previous studies from our laboratory have identified the location of a single amino acid residue at position 381 within the human AHR ligand-binding domain (LBD) that is permissive for high or low exogenous ligand binding affinity (Ema, et al. 1994; Ramadoss and Perdew 2004) . The human AHR gene encodes V381, resulting in a 10-fold reduction in the affinity of the AHR for a radiolabelled dioxin analog, compared to the A381 variant observed in mouse. These observations prompted an examination of AHR sequences from archaic hominins and non-human primates to examine the phylogenetic history of diminished PAH sensitivity. We first considered a database of genome-wide gene coding region ('exome') variants among population samples of humans (n=9 individuals or n=18 diploid chromosomes), Neandertals (n=3 individuals; n=6 chromosomes), and one Denisovan individual (an archaic hominin population more closely related to Neandertals than modern humans; n=2 chromosomes), based on paleogenomic sequence data (Meyer, et al. 2012; Castellano, et al. 2014; . We found that, first, while the AHR is highly conserved overall (supplementary fig. 1 ), Neandertals and the Denisovan individual are fixed for the ancestral variant at codon 554 (predicted amino acid K554), while humans are variable at this position (R554 or K554) (Wong, et al. 2001) . Currently, no functional consequence has been ascribed to the R↔K554 polymorphism in humans. Second, and most interestingly, based on the presently available paleogenomic sequence data, Neandertals and Denisovans are fixed for the ancestral variant at codon 381 (A381) whereas humans are fixed for a derived variant at this position (V381) ( fig. 1 ). In fact, this amino acid residue is invariant among any human whose genome has yet been sequenced (e.g., via the 1000
Genomes project, or reported in the dbSNP database) and the oldest (45, 000 y) anatomically ). This situation is unusual across the genome. In the Neandertal and Denisovan paleogenomic database (Castellano, et al. 2014) Furthermore, the AHR was only protein on this list that is involved in adaptation to environmental stimuli (e.g. xenobiotic metabolism).
The human AHR exhibits reduced activation by PAHs compared to the Neandertal receptor
The archaic hominin A381 variant, located within the AHR LBD, is shared with non-human primates and other vertebrates, e.g. rodents, which exhibit enhanced TCDD and PAH binding compared to humans (Harper, et al. 1988; Poland, et al. 1994; Ramadoss and Perdew 2004) . It is important to point out that there are a number of non-conserved amino acid differences within the human compared with mouse AHR LBD (Supplementary fig. 2 ). In silico molecular modeling of the Neandertal AHR LBD in complex with B(a)P indicates that A381 is centrally 
The human and Neandertal AHR exhibit similar levels of activation by endogenous ligands
As a xenobiotic sensor, the AHR is activated by many polycyclic aromatic ligands and other xenobiotics, however, the increasing number of physiological functions attributed to AHR are activated by endogenous and diet-derived ligands, such as kynurenic acid, indirubin, indoxyl-3-sulfate and indole. We therefore examined whether the adaptive A→V381 desensitization to polycyclic aromatic ligands observed in human AHR also impacted sensitivity to endogenous ligands, compared to the AHR in Neandertal and other non-human primates. Studies using indirubin, indoxyl-3-sulfate and indole ( fig. 4A ), previously reported to exhibit enhanced binding to human AHR over mouse AHR (Flaveny, et al. 2009; Hubbard, et al. 2015 ancestors acquired and retained a specific loss of sensitivity to exogenous ligand mediated activation of the AHR acquired through mutation of A→V381 during the course of hominin evolution. Importantly, the V381 variant is fixed among all modern humans within the available genome sequence data, despite evidence of human-Neandertal admixture and some introgression of Neandertal alleles into the gene pools of non-African modern humans (Vattathil and Akey 2015) , raising the possibility of a selective advantage associated with the V381 AHR variant.
Given the loss of sensitivity to exogenous ligands in humans, it is probable that the metabolic processes governed by the AHR would be altered. It is evident that humans are capable of effectively metabolizing PAHs leading to metabolic elimination, such as is the case for smokers.
However, a greater degree of induction of CYP1A1 metabolism in non-human primates may lead to a relatively high level of toxic intermediates, without necessarily achieving a greater overall clearance rate, leading to toxic outcomes. Therefore, we postulate that exposure to sources of potentially toxic environmental AHR ligands may have been associated with strong selection pressure for mutations affecting the relative desensitization of AHR to exogenous ligands.
The precise evolutionary origin of the highly conserved A→V381 AHR mutation is difficult to assess due to the current absence of anatomically modern human lineage paleogenomic sequences prior to 45,000 ya. Nevertheless, the AHR underwent a change within its ligandbinding domain, perhaps facilitating a degree of resistance to the consequences of environmental exposures. In contrast, the similar sensitivity to endogenous ligands within Hominoidea suggests that human AHR responsiveness to these ligands was acquired prior to divergence of the primate lineage and has persisted ever since; perhaps supporting the pivotal role for endogenous ligandmediated AHR physiological functions in primates, including humans. This fact also supports the high level of specificity in the mutation that actually occurred. Furthermore, these data could living approximately 300-500 ka (Endicott, et al. 2010) , were probably able to control fire (Gowlett and Wrangham 2013) . The controlled uses of fire likely expanded the hominin niche, with uses for warmth, cooking, the heat treatment of tools and making pigments, and potentially landscape modification (Hovers, et al. 2003; Brown, et al. 2009; Parker, et al. 2016 ).
Localization of fire in caves was common, indicating a partly troglodytic existence, and placement of central hearths in the depths of caves appears to have been associated with intensity of cooking, flint knapping, and animal processing activities (Hardy, et al. 2015) . Evidence of micro-fragments of charcoal in Lower Paleolithic hominin dental calculus is consistent with smoke inhalation, and suggests that smoke remediation in caves and other structures may have been a problem (Hardy, et al. 2015; Monge, et al. 2015) . It has been theorized that cooking The routine use of controlled fire carried a cost. Smoke derived from the incomplete combustion of wood and other organic material generates particulates containing a multitude of irritants and toxic chemicals, including polycyclic aromatic hydrocarbons (PAHs), which at high concentrations can result in acute toxic responses and subsequent chronic toxicities, leading to morbidity and exacerbation of co-morbidities (Zelikoff, et al. 2002) . Among morbidities associated with chronic smoke inhalation are acute respiratory infection and a high risk of low birth weight and infant mortality due to maternal exposure (Smith, et al. 2000) . Indeed, exposure to AHR ligands can mediate adaptive immune suppression in part through induction of Treg cells, which may increase susceptibility to viral or bacterial infections (Huang, et al. 2013; Bruhs, et al. 2015; Yang, et al. 2016 ). In addition, PAH exposure can mediate an increased time to pregnancy, reduced spermatogenesis and increased apoptosis of oocytes (MacKenzie and Angevine 1981; Matikainen, et al. 2001; Revel, et al. 2001; Esakky and Moley 2016) . Many
PAHs elicit cellular toxicity through damaging electrophilic intermediates generated as a consequence of metabolism. The prototypical example of such a PAH is benzo(a)pyrene (BaP), which is capable of inducing its own metabolism to generate highly reactive B(a)P epoxides.
Upon respiratory and dermal exposure to excessive smoke-derived PAHs, AHR/ARNT-mediated CYP1A1/1B1 expression is elevated to supra-physiological levels, resulting in relatively high concentrations of toxic PAH metabolic intermediates. Excessive rapid metabolism of PAHs to reactive intermediates can result in cellular necrosis and death in rodents (Uno, et al. 2001) . 
Materials and Methods
Reagents
TCDF was obtained from AccuStandard. 1,2-benz(a)anthracene and benzo(a)pyrene were purchased from Sigma. Indoxyl-3-sulfate and indirubin were purchased from Alfa Aesar and Enzo Life Sciences, respectively. Indole was purchased from Sigma and purified as previously described (Hubbard, et al. 2015) . The photoaffinity ligand 2-azido-3-[ 125 I]iodo-7,8-dibromodibenzo-p-dioxin was synthesized as described (Poland, et al. 1986 ). Cultured supernantant from monoclonal antibody hybridoma clone RPT1 was produced as previously described (Perdew, et al. 1995) . COS-1 and BP8 cells were obtained from American Type
Culture collection (Manassas, VA) and Martin Göttlicher (Institute of Toxicology and Genetics, Eggenstein, Germany), respectively. BP8 cells are deficient in AHR expression and were generated as described (Weiss, et al. 1996 ).
Plasmids and mutagenesis
The H. sapiens, P. trogloytes, and C. sabaeus AHR cDNA optimized for mammalian codon use and minimal secondary mRNA structure were synthesized by GenScript (Piscataway, NJ) and were inserted into pcDNA3. The nucleotide sequences for these cDNAs are shown in supplemental figure 5. The plasmid pSV-Sport1-ARNT was kindly provided by Oliver
Hankinson (University of California, Los Angeles). Electrophoretic mobility shift assays were performed using in vitro translated AHR of a given specific species as indicated and human ARNT. All other aspects of these assays were performed as previously described (Chiaro, et al. 2008 ).
Electrophoretic Mobility Shift Assays
Cell Culture. COS-1 and BP8 cell lines were maintained in α-modified essential media (SigmaAldrich, St. Louis, MO) supplemented with 10% fetal bovine serum (Hyclone Laboratories, Logan UT). Cells were cultured at 37 °C in a humidified atmosphere composed of 95% air and 5% CO 2 in the presence of 100 IU/ml penicillin and 100 µg/ml streptomycin (Sigma-Aldrich).
AHR Ligand Binding Assay
COS-1 cells were grown to 90% confluency in 6-well cell culture plates. Cells were transfected using the Lipofectamine ® 2000 transfection reagent and PLUS TM reagent (Life Technologies, Carlsbad, CA) with 1.5 µg of AHR plasmid construct per well, according to the manufacturer's protocol. All binding experiments were performed in the dark prior to photo-crosslinking. These experiments were done essentially as described previously (Swanson and Perdew 1991; Ramadoss and Perdew 2004) . Media from the transfected cells in six-well plates was removed, and fresh media containing the appropriate amount of photoaffinity ligand was added to each well. Fresh media containing 0, 0.5, 1.0, 1.5, 2.0, or 2.5 pmoles of AHR photoaffinity ligand, 2-azido-3-[ 125 I]iodo-7,8-dibromodibenzo-p-dioxin was applied to cells for 1 h (in duplicate) at 37⁰C in 95% air/5% carbon dioxide. The bound PAL was cross linked to AHR via UV cross linking (302 nM) for 4 min at a distance of 8 cm. Cells were then lysed in 200 µL of lysis buffer [MENG, pH 7.28, 20 mM sodium molybdate, 500 mM sodium chloride, protease inhibitor cocktail and 1%(v/v) NP-40]. Samples incubated on ice and were spun at 13,000 x g for 10 min.
A volume of 50 µL of the lysate supernatant per sample was resolved upon an 8% Tricine/SDS polyacrylamide gel. Protein and bound PAL were transferred to polyvinylidene fluoride (PVDF) membrane and visualized by autoradiography. Band intensities were quantified by filmless autoradiographic analysis using a Cyclone storage phosphor screen instrument (PerkinElmer Life and Analytical Sciences). Band intensities were determined by γ-counting or filmless autoradiographic analysis, and both methods yield similar results.
BP8 cell transfection/AHR ligand dose-response Assays
Rat hepatoma BP8 cells that lack AHR expression were plated to 90% confluency in 12-well cell culture plates and transfected using the Lipofectamine 
Real-time PCR Primers
Rat Cyp1a1-F 5ꞌ-CCC TAA CTC TTC CCT GGA TGC-3ꞌ
Rat Cyp1a1-R 5ꞌ-GGA TGT GGC CCT TCT CAA ATG-3ꞌ
Rat Cyp1b1-F 5ꞌ-GAC ATC TTTG GAG CCA GCC A -3ꞌ
Rat Cyp1b1-R 5ꞌ-TCC GGG TAT CTG GTA AAG AGG A -3ꞌ
Rat Rpl13a-F 5ꞌ-AAG CAG CTC TTG AGG CTA AGG -3ꞌ
Rat Rpl13a-R 5ꞌ-TGG GTT CAC ACC AAG AGT CC -3ꞌ
Plasmid Mutagenesis
The Neandertal AHR expression and mutant constructs were synthesized by QuikChange SiteDirected Mutagenesis (Agilent Technologies, Wilmington, DE) of the corresponding synthetic human AHR construct (pcDNA3.syn.hAHR) according to manufacturer's protocols. The V381A and R554K codons were altered to generate the Neandertal AHR cDNA.
Mutagenesis Primers
hAHR-V381A-F 5ꞌ-GAT TAC ATC ATC GCT ACC CAG CGG CCC-3ꞌ
hAHR-V381A-R 5ꞌ-GGG CCG CTG GGT AGC GAT GAT GTA ATC -3ꞌ
hAHR-R554K-F 5ꞌ-CCT GGG CAT CGA TTT CGA AGA CAT CAA GCA CAT GCA GAA CG -3ꞌ hAHR-R554K-R 5ꞌ-CGT TCT GCA TGT GCT TGA TGT CTT CGA AAT CGA TGC CCA GG -3ꞌ
Protein electrophoresis and blot analysis
Cells were lysed in RIPA buffer as previously described , protein resolved by Tricine SDS-PAGE, and transferred to polyvinylidene difluoride membrane.
The relative level of AHR was determined using mAb RPT 1, a biotinylated goat anti-mouse IgG secondary antibody and [ 125 I]streptavidin. B-actin detected with mAb B-actin (C4, Santa Cruz Biotechnology) was utilized as a loading control.
In silico molecular modeling. The homology model of the human AhR-PASB-LBD based on the NMR apo of the HIF-2a-PASB (PDB 1P97) was prepared and optimized as described (Perkins, et al. 2014) . Molecular docking was run as previously described (Hubbard, et al. 2015) .
Statistical Analysis
Data in the ligand binding assays were analyzed using one-way ANOVA with Tukey's multiple comparison post-test using GraphPad Prism (v.5.01) software to determine statistical significance between treatments. Data represents the mean change in a given endpoint +/-s.e.m.
(n=2/treatment group) and were analyzed to determine significance (**P,0.01; ***P<0.001).
Genomics/Database analysis
We first queried the database of archaic hominin and modern human 'exome' genetic variation produced by Castellano et al. (Castellano, et al. 2014) . The nucleotide variants within this database were identified based on paleogenomic sequence data from three Neandertal individuals (Altai, El Sidron, and Vindija) and one individual from the Denisovan archaic hominin population, plus genome sequence data from nine modern human individuals (three individuals each with sub-Saharan African, European, and Asian ancestry). Genotypes were estimated for only those positions covered by a minimum of six independent sequencing reads in each individual, and ancestral and derived variant states were determined via comparisons to the gorilla and orangutan genome sequences. We used the program PolyPhen-2 (Adzhubei, et al. 2010 ) to infer whether each nucleotide variant in the database was nonsynonymous (amino acid changing; potentially functional) or synonymous (resulting in no change to the amino acid sequence; typically neutral with respect to fitness). Of the 15,383 nonsynonymous SNPs in the database for which ancestral and derived states could also be determined, only 90 were fixed for the derived allele in the modern human sample but the ancestral allele in the archaic hominin sample (Neandertals plus the Denisovan individual). We then queried the dbSNP database (Build 144) to discover that there is no record of variation in modern humans for 27 of these positions. ) and one Denisovan individual (Meyer, et al. 2012) , for which high-coverage genome sequence data are available (these data are also represented in Castellano et al. (Castellano, et al. 2014) database, but with the omission of some lower-coverage sites for the other two Neandertal individuals). For the Neandertal individual, we downloaded the read alignment file from the European Nucleotide Archive (accession ERP002097; L9105.bam) and used the variant detector program called freebayes to reconstruct the Neandertal reference AHR protein sequence (Garrison and Marth 2012) . For the Denisovan sequence, we used an alignment track from the UCSC genome browser (https://genome.ucsc.edu/cgi-bin/hgGateway). We also downloaded the genome sequencing read alignment file for a 45 ky modern human individual (European Nucleotide Archive PRJEB6622) ) and used freebayes for variant calling. Multiple sequence alignments were performed using the program Clustal Omega (Sievers, et al. 2011 ). 
